In our case, we found no CCA-typical BAP1, FGFR2, IDH1, or ERBB2 alterations, but we are aware of the limitations in this study, i.e., a small number of cases and a difference in sequencing methods due to restrictions in predictive testing. This evidence concerns the gene IDH1 and cholangiocarcinoma.